The weekly brief · free to read, free to cite
Hospice and SNF Payment Updates Land Alongside a Wave of New Molecular Entity Approvals
Week of August 17–23, 2026
This week's review spanned twenty-five publications and surfaced five items worth flagging, none tied to a specific MAC, though two carry effective dates already on the calendar. The mix leans toward fiscal-year payment mechanics on one side and newly approved therapeutics on the other, touching hospice, skilled nursing, radiology, cardiology, and hematology billing operations.
CLV Intelligence™ reviewed 25 publications across all 16 Medicare Administrative Contractor jurisdictions this week. 5 are covered below. Every item links its primary government source.
Lead item
CMS Transmittal R13924CP: Update to Hospice Payment Rates, Hospice Cap, Hospice Wage Index and Hospice Pricer for Fiscal…
- Jurisdiction
- National
- Specialty
- Hospice
- Type
- fee_schedule
- Effective
- October 5, 2026
Hospice payment rates, the hospice cap, and the wage index all move together under this fiscal-year pricer refresh, which reaches every hospice claim processed nationally rather than a single MAC jurisdiction.
Item 2
CMS Transmittal R13881CP: October 2026 Quarterly Update to Healthcare Common Procedure Coding System (HCPCS) Codes Used…
- Jurisdiction
- National
- Specialty
- Multi-specialty
- Type
- coding_change
- Effective
- October 5, 2026
This is the quarterly HCPCS refresh that governs consolidated billing enforcement for skilled nursing facilities, meaning the codes SNFs must bundle versus bill separately are being redrawn again ahead of the fall cycle.
Item 3
FDA Approval: TAUKLARIFY (FLORQUINITAU F18) — Type 1 - New Molecular Entity
- Jurisdiction
- National
- Specialty
- Radiology
- Type
- billing_update
- Effective
- August 13, 2026
A newly approved radiodiagnostic agent enters the market as a Type 1 new molecular entity, putting radiology billing teams on notice that reimbursement pathways for this compound have not yet been mapped into existing fee structures.
Item 4
FDA Approval: LEROCHOL (LERODALCIBEP-LIGA) — Type 1 - New Molecular Entity
- Jurisdiction
- National
- Specialty
- Cardiology
- Type
- billing_update
- Effective
- December 12, 2025
This PCSK9-inhibitor approval, dosed as a monthly subcutaneous injection for cholesterol management, sits in cardiology's lane and arrives with an effective date already behind us, meaning any billing infrastructure question is not hypothetical.
Item 5
FDA Approval: ZENBEXUS (IBERDOMIDE) — Type 1 - New Molecular Entity
- Jurisdiction
- National
- Specialty
- Hematology
- Type
- federal_register
- Effective
- August 13, 2026
A new molecular entity approval in hematology, filed here under federal register alert type rather than a standard drug notice, signals this one may carry rulemaking implications beyond a simple label approval.
A week defined less by deadlines than by groundwork: payment mechanics resetting for the fiscal year, and a run of newly approved molecules that billing teams across radiology, cardiology, and hematology will be watching for downstream coding treatment.
See what changed in your jurisdiction
This brief covers the week. The free 90-day snapshot covers your specialty and your MAC — every policy change on record, with its source.
CLV Intelligence monitors and summarizes publicly available federal and MAC publications. It is not legal, medical, billing, or coding advice.